Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00079755 · ClinicalTrials.gov registry record · Phase 2

Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma

A Phase 2 study, sponsored by Seagen.

Completed
Registry status
Phase 2
Development phase
80
Enrollment target

NCT00079755: Completed Phase 2 study, sponsored by Seagen.

NCT00079755 is a Phase 2 study that has completed, run by Seagen. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00079755, a Phase 2 study, has completed, sponsored by Seagen.

COMPLETED
Registry status
Phase 2
Development phase
80 participants
Enrollment target

Study Summary

To investigate safety and antitumor activity of SGN-30 in patients with Hodgkin's Disease and anaplastic large cell lymphoma (ALCL). As of March 22, 2005, interim analysis of the Hodgkin's Disease (HD) arm has been completed per the statistical plan in the protocol. SG030-0003 is now closed to further recruitment of HD patients.

Interventions

  • DRUG SGN-30 (anti-CD30 mAb)

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2004-02
Est. Completion 2006-12
Phase Phase 2
Seagen

84 total trials

What the finished NCT00079755 record still lists

NCT00079755 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).

The record links to 0 conditions, and to 1 intervention - of which SGN-30 (anti-CD30 mAb) is the first listed.

NCT00079755 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00079755 about?

NCT00079755 is a clinical study titled "Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma". To investigate safety and antitumor activity of SGN-30 in patients with Hodgkin's Disease and anaplastic large cell lymphoma (ALCL). As of March 22, 2005, interim analysis of the Hodgkin's Disease (HD) arm has been completed per the statistical plan in the protocol. SG030-0003 is now closed to furt...

What is the current status of trial NCT00079755?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2004-02. Estimated completion is 2006-12.

What interventions are being tested in trial NCT00079755?

The interventions under investigation include: SGN-30 (anti-CD30 mAb) (DRUG).

Who is sponsoring clinical trial NCT00079755?

This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00079755's enrollment target sits among peer trials

80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00079755, the US trial registry maintained by the National Library of Medicine. NCT00079755 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.